Quidditas Therapeutics has developed a groundbreaking genome editing technology known as GREAT, which aims to address the limitations of existing genome editing tools like CRISPR-Cas9. Unlike traditional methods that face challenges related to efficiency and specificity, GREAT allows for precise cutting and pasting of nucleic acid sequences—both RNA and DNA—anywhere in the genome. This innovative approach enables targeted and controlled excision, facilitating absolute genetic recombination. As a result, GREAT can replace entire genes or exons by excising selected sequences and integrating new double-stranded sequences, thereby expanding the potential applications in various fields, including genetic disorders, oncology, organ transplantation, and even environmental and food industry improvements.

In addition to its therapeutic applications, Quidditas is focused on fostering collaborations with partners in the pharmaceutical and biotech industries to explore new genetic targets and develop novel treatments using their proprietary technology. The GREAT technique not only enhances gene therapy but also serves as a bioprocess booster for routine research applications. Quidditas is actively seeking strategic partnerships to further advance their innovative solutions and contribute to the evolution of biotechnology and medicine.

Belgium

Genome editing-based therapies become the predominant technology of the 21st century with promising statements about genetic diseases treatments. Genome editing tools recently emerged but they suffer from an absence of standardization and their applications remain limited.
In this context, Quidditas developed a novel genome editing platform which permits an absolute genetic recombination.
Compatible with a larger scope of applications, from bioprocess improvement to genetic disorders treatment, this revolutionary technique will have a major impact in the synthetic Bio field.

So "Let's cure from the beginning!"

QUIDDITAS

Company Details